AZNAstraZenecaRunning, no new patients
A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2
Gastric Cancer · Gastroesophageal Junction Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 33 (final count)
- Started
- Aug 29, 2025
- Main results expected
- Aug 14, 2026
- Fully finished
- Sep 28, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response Rate (ORR)
Measured over: At month 6 after date of first dose
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07143604 · record last updated 2026-09-30 · checked 2026-11-09 15:47 UTC